A Mother Held Up Her Son's Photo in Tucson. Washington Wants to Cut the Program That Might Have Saved Him.

Theresa Guerrero brought a poster board to a public library in Pima County on Aug. 19. On it was her son Jacob’s face, enlarged enough to see from the back of the room. Jacob didn’t die from an opioid he sought out — he died after using cocaine that had been laced with fentanyl, a drug he almost certainly never chose to take at all. Guerrero stood next to Arizona Attorney General Kris Mayes and congressional candidate JoAnna Mendoza at an event at Nanini Library, one of two Arizona mothers there that day who had already buried a child to fentanyl poisoning.

Nobody in that room needed the politicians to explain what fentanyl is. They needed someone to explain why it’s still this easy to die from a drug you didn’t know you took, two years into a national overdose decline.

It’s not over in Arizona. Two days after Guerrero stood in that library, the DEA marked the fifth annual National Fentanyl Prevention and Awareness Day by announcing real, measurable progress against the drug that killed her son.

Washington wants credit for shrinking the supply of fentanyl while it quietly tries to kill the funding that reverses an overdose when the supply gets through anyway.

That’s not a contradiction buried in a budget spreadsheet. It’s the whole story of this week in drug policy, and it’s worth sitting with before the next round of statistics makes it feel abstract again.

The Poster in the Library Was the Point, Not the Politicians

Guerrero and the second mother at Nanini Library weren’t there to endorse a candidate. According to the Tucson Sentinel’s reporting on the event, the mothers used the platform Mayes and Mendoza gave them to push for something specific and unglamorous: wider distribution of fentanyl test strips — cheap paper strips, often under a dollar each, that tell a person whether their drugs are contaminated with fentanyl before they use, not after — and broader access to naloxone, the medication (sold under the brand name Narcan) that can reverse an opioid overdose in real time, often in under two minutes, if someone is there to give it.

That ask matters because of how Jacob died. He wasn’t a person who set out to use fentanyl. Cocaine users are among the fastest-growing group of fentanyl deaths nationally precisely because they have no reason to expect an opioid in their supply and often no tolerance to survive even a small amount if it’s there. A test strip costs less than a candy bar and takes under a minute to use. It would not have required Jacob to change what he was doing that night — only to know what was actually in his hand.

This is the piece of the story that gets lost when the conversation moves to Capitol Hill: the mothers at that library were not asking for a philosophical shift in how America thinks about drug use. They were asking for strips and naloxone kits to be sitting somewhere Jacob could have reached them. Mayes, as Arizona’s top law enforcement official, and Mendoza, running for a congressional seat, showed up to amplify a request that predates both of their political timelines by years — advocates in harm reduction have been making this exact case since fentanyl started showing up in the stimulant supply, not just the opioid one.

The scene itself said something the speeches didn’t have to: two mothers, a poster, a room full of people who came because they’d lost someone too, or were terrified they might. That’s what National Fentanyl Prevention and Awareness Day actually looks like at ground level, three days before the DEA’s own commemoration in Washington — not a hashtag, but a woman holding up a photograph because it’s the only way left to make her son visible.

The National Numbers Are Real. Arizona Is Proof They Don’t Arrive Automatically

The DEA’s Aug. 21 announcement wasn’t spin. The agency’s own lab testing found that only 29% of fentanyl pills seized and tested in fiscal year 2025 contained a potentially lethal dose — meaning enough fentanyl, as little as two milligrams, about the weight of a few grains of salt, to kill an average adult — down sharply from 76% in fiscal year 2023. Powder purity fell too, from 19.5% to 10.3% over roughly the same stretch. In January and February, Operation Fentanyl Free America Phase II seized 4.7 million pills and 2,396 pounds of fentanyl powder and led to more than 3,080 arrests. In Arlington, Virginia, the DEA Museum’s “Facing Fentanyl” memorial now displays more than 7,000 photographs of Americans killed by the drug — a wall that keeps growing, but growing more slowly than it used to.

In January and February, Operation Fentanyl Free America Phase II seized 4.7 million pills and 2,396 pounds of fentanyl powder and led to more than 3,080 arrests.

Nationally, that tracks with what recovery advocate Ryan Hampton wrote in an Aug. 14 op-ed for The Hill: overdose deaths fell 27% in 2024, one of the steepest annual declines the country has recorded. Hampton, who is in long-term recovery himself, doesn’t treat that number as a victory lap. He treats it as fragile. “When money gets tight, mental health care is the first thing families give up and the last thing they get back,” he wrote — and he’s arguing specifically that the same forces producing this decline are now under direct threat.

Arizona is where that fragility stops being theoretical and starts being visible in the data right now, not hypothetically. Axios Phoenix reported in July that the state’s overdose death rate runs roughly double the national average — and Arizona is the only state in the country still above its pandemic-era peak, even as the national rate has fallen sharply. Every other state has come down off its worst year. Arizona hasn’t. Guerrero didn’t lose Jacob in a state where the crisis is winding down. She lost him in the one state where the national success story doesn’t apply yet.

That gap is the argument for exactly what the mothers at Nanini Library were asking for. National seizure numbers and pill-testing statistics are upstream interventions — they matter, and they’re genuinely working. But they don’t reach the person standing in a bathroom with a bag of cocaine that happens to be cut with fentanyl. Only a test strip in that bathroom, or naloxone in the hands of whoever’s nearby, reaches that moment. Arizona’s numbers suggest the upstream progress hasn’t fully translated into downstream protection yet — which makes it a strange week for Washington to be discussing whether to fund less of the downstream part.

The Same Week DEA Claimed Progress, HHS Proposed Cutting What Makes It Stick

Here’s the part of the story that turns a sad local event into a national argument. CBS News reported that the Trump administration has proposed eliminating a $56 million SAMHSA grant — SAMHSA is the Substance Abuse and Mental Health Services Administration, the federal agency that funds most of the country’s addiction and mental health infrastructure — that specifically trains first responders, police officers, and EMTs to administer naloxone. It’s not a grant for research or awareness campaigns. It pays for the actual training that puts a reversal drug into the hands of the people most likely to arrive first when someone stops breathing.

The proposal sits inside a much larger $33.3 billion package of HHS budget cuts, which CBS reports includes roughly $1.7 billion in cancelled SAMHSA block grants — lump-sum funding the federal government sends to states to spend on treatment and prevention programs as they see fit — and $350 million cut specifically from addiction and overdose-prevention funding. All of this is being proposed at the exact moment the DEA is publicly celebrating that fewer pills on the street are lethal, and Ryan Hampton is publicly warning that the gains are reversible.

They’re connected, and pretending otherwise is the actual dishonesty here. Fewer lethal pills on the street is a supply-side win. It does nothing for the person who still finds one, or still gets a bag of cocaine cut with fentanyl the way Jacob did. That’s what naloxone training funds, and Medicaid — the government insurance program that pays for a large share of addiction treatment nationwide — cover: not prevention of exposure, but survival of exposure. Hampton’s op-ed ties both threats together directly, warning that projected Medicaid cuts could strip coverage from 10 million people, gutting exactly the treatment infrastructure that turns an overdose reversal into a second chance rather than a delayed death.

It does nothing for the person who still finds one, or still gets a bag of cocaine cut with fentanyl the way Jacob did.

You don’t have to trust a politician’s framing of any of this to see the shape of it. The DEA press release and the CBS reporting on the proposed cuts were published three weeks apart, describing the same federal government pursuing opposite strategies at the same time — spending aggressively to interdict fentanyl before it reaches anyone, while proposing to spend less on what happens for the people it reaches anyway. Jacob wasn’t stopped by interdiction. Nothing in the DEA’s seizure numbers was ever going to catch a bag of cocaine cut with fentanyl before it got to him. The only thing that could have changed what happened to him was a test strip in his hand or naloxone in someone else’s — the exact category of spending now on the table for cuts.

We’ve Fought This Fight Before, Over the Same Cheap, Boring Thing

This isn’t the first time the country has treated a cheap, life-saving tool as politically radioactive. In the mid-2010s, naloxone was still largely locked behind a prescription in most states, even though it has no abuse potential — it does nothing to someone who isn’t overdosing on opioids. Programs like Project Lazarus in North Carolina and a wave of state “standing order” laws between 2013 and 2016 fought to get naloxone into the hands of family members and first responders without a doctor’s visit first. Opponents argued, explicitly, that easy access created “moral hazard” — that saving someone without consequence would encourage more drug use. That argument delayed access for years before public health data won and pharmacies nationwide began stocking it over the counter.

The naloxone-training grant on the chopping block now is a direct descendant of that fight. It’s the same argument in different clothes: whether it’s worth spending money to make sure the person standing next to someone overdosing has both the drug and the training to use it. We already litigated this once and reversed course because the moral-hazard theory didn’t survive contact with the death toll. Proposing to cut the training funds now is proposing to relearn that lesson from scratch, with a fresh set of names on the DEA Museum’s wall while we do it.

What’s Still Yours Tonight, Regardless of What Congress Does

None of the proposed cuts have taken effect yet. Naloxone is still available over the counter at pharmacies nationwide right now, tonight, no prescription required. In Massachusetts alone, the state Department of Public Health distributed 405,278 doses of naloxone in the past fiscal year to first responders, schools, and harm reduction programs — proof that this infrastructure is not hypothetical, not something waiting on a future budget fight to exist. It is funded, distributed, and working in communities right now, this week, while the fight over next year’s budget plays out separately.

If you’re in recovery, or still using, or sitting with someone you love who is: fentanyl test strips remain legal to possess in most states, including Arizona, and naloxone doesn’t require you to justify why you want it. You don’t need a diagnosis, a treatment plan, or anyone’s permission to carry either one. You have seen worse than a budget line item — you’ve probably seen the moment a test strip or a nasal spray was the only thing standing between someone you love and a poster board at a library. That’s not a hypothetical for you. It’s Tuesday.

Theresa Guerrero didn’t bring a poster of her son to a library in Pima County because she thought it would change a federal budget line by itself. She brought it because a photograph is what’s left when the systems meant to catch someone before it happens don’t, and because the alternative to showing his face is letting Jacob become a statistic that fits neatly inside a DEA press release about declining pill potency — accurate, encouraging, and beside the point for the family that lost him anyway.

Theresa Guerrero didn’t bring a poster of her son to a library in Pima County because she thought it would change a federal budget line by itself.

The national numbers really are improving. That’s not spin, and it shouldn’t be waved away out of grief or cynicism — fewer lethal pills on the street is a real, hard-won result of real enforcement work. But Arizona’s overdose rate hasn’t followed the national curve down, and the gap between what’s true nationally and what’s true for a family in Pima County is exactly where the naloxone-training grant, the test strips, and the Medicaid coverage under threat right now actually live. Cut those, and you’re not touching an abstraction. You’re touching the one variable that was ever actually available to change what happened to Jacob.

The question the DEA’s own statistics leave open isn’t whether the country is making progress against fentanyl. It clearly is. The question is whether Washington is willing to keep paying for the part of that progress that shows up in a bathroom, a car, a bedroom — the part that doesn’t get a press release, only a mother holding up a photograph and asking a room full of strangers to look at her son’s face one more time.